XTX Topco Ltd Takes Position in DexCom, Inc. (NASDAQ:DXCM)

XTX Topco Ltd bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 29,104 shares of the medical device company's stock, valued at approximately $1,951,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Jennison Associates LLC grew its holdings in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock worth $464,782,000 after buying an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after buying an additional 876,739 shares during the last quarter. Two Sigma Advisers LP grew its holdings in DexCom by 182.7% in the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company's stock valued at $76,659,000 after purchasing an additional 739,000 shares during the period. Canada Pension Plan Investment Board grew its stake in shares of DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company's stock valued at $75,471,000 after buying an additional 435,401 shares during the period. Finally, Intech Investment Management LLC raised its holdings in shares of DexCom by 2,083.0% in the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company's stock worth $25,967,000 after purchasing an additional 369,587 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Price Performance

Shares of NASDAQ:DXCM traded down $1.20 during trading on Friday, reaching $77.72. The company had a trading volume of 2,644,207 shares, compared to its average volume of 3,793,395. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm's fifty day moving average is $72.55 and its 200 day moving average is $85.74. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The firm has a market capitalization of $30.36 billion, a PE ratio of 46.54, a price-to-earnings-growth ratio of 2.48 and a beta of 1.12.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company increased their price objective on shares of DexCom from $80.00 to $90.00 and gave the stock an "overweight" rating in a research report on Friday, October 25th. Sanford C. Bernstein raised their price objective on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. StockNews.com downgraded DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Royal Bank of Canada dropped their target price on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Finally, Piper Sandler reissued an "overweight" rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and a consensus target price of $104.59.

Insider Activity

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 4,259 shares of the firm's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,431 shares of company stock worth $399,319. Company insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.